The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 49.475. At the end of 2022 the company had a P/E ratio of 24.3.
Year | P/E ratio | Change |
---|---|---|
2022 | 24.3 | 16.29% |
2021 | 20.9 | -43.89% |
2020 | 37.2 | 122.84% |
2019 | 16.7 | -35.26% |
2018 | 25.8 | -11.41% |
2017 | 29.1 | 70.28% |
2016 | 17.1 | -8.47% |
2015 | 18.7 | -68.3% |
2014 | 58.9 | 188.94% |
2013 | 20.4 | 92.03% |
2012 | 10.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 14.9 | -69.84% | ๐บ๐ธ USA |
Eli Lilly LLY | 143 | 189.62% | ๐บ๐ธ USA |
Amgen AMGN | 20.1 | -59.39% | ๐บ๐ธ USA |
Biogen BIIB | 11.7 | -76.39% | ๐บ๐ธ USA |
Gilead Sciences GILD | 16.7 | -66.27% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 13.7 | -72.39% | ๐บ๐ธ USA |
AstraZeneca AZN | 34.1 | -31.01% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | 12.2 | -75.25% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | 70.4 | 42.23% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.